Skip to main content
AVACTA GROUP PLC logo

AVACTA GROUP PLC — Investor Relations & Filings

Ticker · AVCT ISIN · GB00BYYW9G87 LEI · 2138009U3EG31OPMGH36 IL Manufacturing
Open in API
Filings indexed 708 across all filing types
Latest filing 2021-03-03 Regulatory Filings
Country GB United Kingdom
Listing IL AVCT

About AVACTA GROUP PLC

https://avacta.com/

Avacta Group PLC is a clinical-stage biotechnology company developing targeted oncology drugs. The company's core technology is the proprietary pre|CISION® platform, a drug delivery system designed to improve the safety and efficacy of potent cancer therapies. The platform works by linking a peptide to a cancer drug, rendering it inactive in the bloodstream. The drug is precisely activated only within the tumor microenvironment by the Fibroblast Activation Protein (FAP) enzyme, which is abundant in many solid tumors. This approach aims to concentrate the active therapy at the tumor site, thereby reducing systemic toxicity and improving the therapeutic window for patients. The company is advancing a pipeline of peptide drug conjugates (PDCs) based on this platform.

Recent filings

Filing Released Lang Actions
Electronic Communications with Shareholders
Regulatory Filings Classification · 99% confidence The document is identified by the RNS Number format ('0899R') and contains a date (03 March 2021). The content explicitly states that the company 'announces that it has today posted a letter concerning electronic communications to its new shareholders' and that 'The letter will be available on the Investors section of Company's website'. Furthermore, the footer explicitly states, 'Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature.' This structure—announcing the availability of a document (a letter) via a non-regulatory news service (Reach/RNS)—strongly indicates a general announcement rather than the full report itself. Since it is an announcement about company communication/information that doesn't fit specific categories like DIV, ER, or MANG, the most appropriate classification is the general regulatory/news announcement fallback, RNS.
2021-03-03 English
Business Update
Regulatory Filings Classification · 95% confidence The document is dated February 24, 2021, and is titled 'Business Update: Significant momentum in both Diagnostics and Therapeutics Divisions'. It details operational highlights, corporate progress, and provides commentary from the CEO regarding developments in the Diagnostics and Therapeutics divisions, including clinical trial authorizations and partnership agreements. It mentions that preliminary results for the financial year ended 31 December 2020 are expected mid-April. This structure—a comprehensive update on business activities, operational progress, and pipeline milestones, often released outside of standard quarterly/annual filing dates—is characteristic of a general business update or an announcement that precedes a formal financial report. Since it is a detailed update covering multiple operational areas and is not a transcript (CT), a formal Annual Report (10-K), or a short announcement of a report release (RPA), it best fits the category for general corporate/investor information. Given the detailed nature of the operational and pipeline progress, it is more substantial than a simple Earnings Release (ER) which focuses only on key financial figures. However, it is not a formal regulatory filing like a 10-K or IR. It functions as a detailed investor communication. Among the provided options, 'Regulatory Filings' (RNS) is the most appropriate fallback for significant, non-standard corporate announcements that don't fit the specific financial report codes, especially since it is distributed via RNS (RNS Number : 1123Q). It is a detailed business update, which often falls under general regulatory disclosure.
2021-02-24 English
Re: Press Speculation
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated '22 February 2021'. It addresses 'recent press speculation' regarding the company's SARS-CoV-2 rapid antigen test and provides an update on clinical data and ongoing validation efforts. The text concludes with standard disclaimers from RNS, the news service of the London Stock Exchange, stating that RNS is approved by the Financial Conduct Authority (FCA) to act as a Primary Information Provider. This structure—a brief announcement addressing a specific market event (press speculation) and providing operational updates, disseminated via the RNS system—is characteristic of a general regulatory announcement that doesn't fit a more specific financial report category (like 10-K, ER, or IR). Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (7305 chars) is substantial enough that it is not merely an announcement of a report (RPA), but the report itself, which in this context is a general regulatory disclosure.
2021-02-22 English
Phase I CTA for AVA6000 Approved by MHRA
Legal Proceedings Report Classification · 99% confidence The document begins with an 'RNS Number' and is dated February 18, 2021. The content announces that Avacta Group plc has received approval from the MHRA for a Clinical Trial Authorisation (CTA) for its AVA6000 Phase I study. This is a specific, material announcement made via the Regulatory News Service (RNS) system of the London Stock Exchange. While it contains detailed operational and clinical information, its primary function is to disseminate a regulatory update to the market immediately. It is not a full Annual Report (10-K), an Earnings Release (ER), or a comprehensive Interim Report (IR). Since it is a formal, non-standard regulatory announcement disseminated through the RNS system, and it doesn't fit neatly into the other specific categories like DIRS, DIV, or CAP, the most appropriate classification is the general regulatory filing category, RNS.
2021-02-18 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is identified by the 'RNS Number' header and explicitly mentions 'RNS, the news service of the London Stock Exchange'. The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a specific type of market announcement. This type of general regulatory announcement that doesn't fit into the more specific categories (like 10-K, ER, DIV, etc.) is best classified under the general Regulatory Filings category (RNS). The document length is short (1934 chars), but it is the primary announcement itself, not an announcement *of* another report.
2021-02-16 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1917 characters) and contains the header 'RNS Number : 2451P'. It announces a 'Price Monitoring Extension' related to trading on the London Stock Exchange. It explicitly states that the information is provided by RNS, the news service of the London Stock Exchange, and mentions the Financial Conduct Authority (FCA). This is a general regulatory announcement that does not fit the specific definitions for financial reports (10-K, IR, ER), corporate actions (DIV, SHA), or management changes (MANG). Therefore, it falls best under the general Regulatory Filings category (RNS) as a miscellaneous regulatory update.
2021-02-16 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.